Imatinib, a first-generation tyrosine kinase inhibitor (TKI), revolutionized the treatment of CML by targeting the BCR-ABL protein, leading to significant improvements in survival rates [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.